Archive for March, 2018

$SENS Favorable Outcome of FDA Advisory Committee on Eversense

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices meeting on the Eversense system. The panel, comprised of independent medical experts, voted unanimously, 8 to 0, that the benefits outweigh the risks, voted unanimously, 8 to 0, that the system is safe, and voted unanimously, 8 to 0, that the system is effective.

“We are pleased that the advisory panel believes in the benefits of the Eversense system. We are confident that the benefits of the system – longest life sensor, sustained accuracy, predictive glucose alerts, removable smart transmitter, gentle-on-skin adhesive – can be life changing for people with diabetes, and this is another step toward offering these benefits to patients in the U.S.,” stated Tim Goodnow, President and Chief Executive Officer of Senseonics. “We thank the panel members, the participants in today’s meeting, the clinical trial participants and the FDA, and are eager to continue the positive dialogue with FDA in pursuit of approval for Eversense.”

The Eversense system is a first of its kind implantable continuous glucose monitoring system utilizing a sensor that lasts for up to 90 days. The company demonstrated safety, efficacy and a favorable risk benefit profile for Eversense through real world data from patients currently using the system in Europe and data from the U.S. PRECISE II study. The study is considered one of the largest studies of a CGM system in the world, including over 2 million sensor glucose readings, from 90 participants at eight clinical centers.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ CGM systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for Senseonics, including statements about the timing of FDA review and the potential U.S. launch of Eversense and other statements containing the words “expect,” “intend,” “may,” “will,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to the recommendation of the panel with respect to the PMA, the ultimate decision by the FDA with respect to the PMA, timing of any such decision and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2017, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

 

Senseonics Holdings, Inc.
Investor Contact
R. Don Elsey
Chief Financial Officer
301-556-1602
don.elsey@senseonics.com

Thursday, March 29th, 2018 Uncategorized Comments Off on $SENS Favorable Outcome of FDA Advisory Committee on Eversense

$AKG to Receive US$185 Million From Gold Fields for 50% Joint Venture

VANCOUVER, British Columbia, March 29, 2018 — Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE American:AKG) is pleased to announce that it has entered into certain definitive agreements under which Asanko will receive US$185 million for a 50% joint venture (“JV”) interest in its Asanko Gold Mine (“AGM”) from subsidiaries of Gold Fields Limited (“Gold Fields”) (JSE:GFI) (NYSE:GFI), one of the world’s largest gold producers and the second largest gold producer in Ghana.

Under the various transaction agreements (“Transactions”), Asanko and Gold Fields will, among other things, form an incorporated 50:50 corporate JV which will own Asanko’s 90% interest in the Asanko Gold Mine (the “AGM”) and all associated properties in Ghana. The Government of Ghana will continue to hold a free-carried 10% interest. In addition to the JV interest, Gold Fields will purchase a 9.9% shareholding interest in Asanko for approximately US$17.6 million to purchase 22,354,657 shares at approximately US$0.79, equal to the 5-day VWAP as of market close on March 27, 2018. Asanko will host an investor conference call at 9am ET today, details below.

Transaction Highlights

  • Asanko will receive from Gold Fields:
    • US$165 million in cash, payable upon closing of the JV Transaction expected before end of Q3 2018
    • US$20 million in cash, also payable for the JV Transaction, on an agreed Esaase development milestone but in any event no later than December 31, 2019
    • US$17.6 million from Gold Fields for a 9.9% private placement in Asanko shares at a price of US$0.79 anticipated to be completed in the immediate future
  • Asanko will remain the manager and  operator of the AGM and will continue to be paid an arm’s length management fee for services rendered to the JV of approximately US$6 million per annum
  • Asanko will use the proceeds primarily to repay its outstanding Red Kite debt of US$164 million
  • Asanko views the JV as a significantly superior outcome than a restructuring of the Red Kite debt facility as it provides a balanced risk/return profile and creates a debt free platform that will enable Asanko to accelerate growth opportunities and pursue its strategy of becoming a mid-tier gold producer

“This transaction presents a unique opportunity for Asanko to de-risk its future production targets whilst at the same time eliminating corporate debt. With a healthy balance sheet and robust operational cash flows, together with a strong technical endorsement, our Life of Mine plan is assured,” said Asanko President and CEO, Peter Breese.

“After carefully weighing the benefits of this transaction, we have determined that it is superior to the alternative of engaging with Red Kite to extend our debt. With the repayment of the Red Kite debt, Asanko has achieved significant financial flexibility moving forward as we seek to continue to grow our business over the medium term.”

“The mine is now operating well within our business targets, with mining efficiencies and the process plant delivering ahead of plan. With this new investment and the freeing up of our balance sheet, we will now move forward with the development of our large scale Esaase deposit, with a view to commencing production in 2019 with an interim trucking operation until the conveyor is fully operational in late 2020. We look forward to working in partnership with Gold Fields and sharing mining and exploration expertise to create added value for all our stakeholders.”

Nicholas Holland, CEO of Gold Fields, commented: West Africa is an important part of our business and we look forward to a long partnership with Asanko in Ghana. We view the Asanko Gold Mine as a high quality asset and a great addition to our existing portfolio of open pit gold operations in the country.”

Transaction Rationale

  • Significantly improved balance sheet
    • Asanko emerges debt free following repayment of Red Kite Facility
    • Strong attributable pro forma cash position of approximately US$35 million (US$55 million including deferred consideration) as at March 23, 2018
  • World-Class Partner with Experience in Ghana
    • Gold Fields is Ghana’s second largest gold producer with more than 20 years of in-country experience
    • Gold Fields brings considerable technical and exploration expertise that complements Asanko’s existing development and operating capabilities
  • Management and Asset Validation
    • Partnership endorses Gold Fields confidence in Asanko’s mine operator capabilities
    • Partnership validates the AGM from a technical and operational perspective
  • Well Positioned for Future Growth
    • Near-term organic growth self funded by the AGM from internally generated cash flows
    • Robust balance sheet with which to fund growth initiatives

Further Transaction Particulars
Under the terms of the Transaction, on closing, Gold Fields will acquire a 50% participating interest in Asanko’s 90% ownership interest in the AGM for an aggregate US$185 million in cash, of which US$165 million is payable upon closing. The remaining US$20 million is payable upon achievement of an agreed Esaase development milestone but in any event by no later than December 31, 2019.

The closing of the Transaction is expected to occur before end of Q3 2018 and is subject to customary conditions precedent including that no material adverse event occurs and Ghanaian Minister of Lands and Natural Resources does not object.

The Transaction will impact the recognition, presentation and measurement of assets and liabilities associated with the Company’s Ghanaian operations. The results of which are expected to result in a non cash impairment charge based on the JV Transaction indicative asset value.

The Joint Venture Agreement
Asanko will remain the manager (operator) of the AGM. A management committee will be formed, with representatives from each party, to govern the operating and development activities of JV. The JV will continue to pay Asanko an arm’s length management fee for services rendered of approximately US$6 million per annum. The JV will fund its growth from operating cash flow. The JV Agreement has customary terms for program participation elections, dilution of equity interest for non-participation, sole risk rights for new projects and expedited dispute resolution.

The Private Placement and Investor Rights Agreement
Gold Fields has agreed to purchase 22,354,657 common shares of the Company through a private placement, at a price of approximately US$0.79 per share (the “Private Placement”) equal to the 5-day VWAP as of market close on March 27, 2018. The net proceeds of the Private Placement will total approximately US$17.6 million, which will further strengthen Asanko’s balance sheet. These shares are subject to a customary four month resale restricted period in Canada. In connection with the Private Placement, Gold Fields will sign an investor rights agreement with Asanko under which Gold Fields will receive certain rights to participate in future Asanko share issuances in order to maintain its 9.9% shareholding for up to five years. In addition, Gold Fields has agreed that it will standstill at this level of ownership for a one year period unless Asanko otherwise consents, and will support Asanko management nominees at shareholder meetings. The Private Placement is anticipated to be completed in the immediate future and has received conditional TSX approval.

Repayment of the Red Kite Debt
Asanko will use the JV Transaction cash to repay in full all outstanding principal and accrued interest (US$164 million) owing to RK Mine Finance Trust I (“Red Kite”) under the Definitive Senior Facilities Agreement upon closing. There are no early repayment penalties associated with the Red Kite debt. Red Kite’s current gold offtake agreement will remain in effect until all outstanding ounces have been delivered to Red Kite or the JV elects to terminate the offtake and pay the associated fee.

In the event that the JV Transaction has not completed by July 1, 2018, when the first principal repayment of the Red Kite debt is due, Gold Fields has also agreed to provide a bridge loan of up to US$20 million for Asanko, to be drawn at Asanko’s sole discretion. The bridge loan will be credited towards Gold Fields’ contribution to the Joint Venture on closing.  If closing does not complete for any reason, the bridge loan will be repayable, after written demand with a 30 day notice, at any time after six months from the date of advance of the bridge loan. If Asanko does not repay the bridge loan, the bridge loan claim would effectively be used to subscribe for new common shares of Asanko, up to the point where Gold Fields would own 19.9% of the outstanding Asanko shares, and the balance would be repaid in cash. Pricing of these shares is subject to TSX policy.

Development of Esaase Proceeding
The development of the large-scale Esaase deposit will commence in 2018 and initial production is expected in Q1 2019 with an interim trucking operation of approximately 1.5 million tonnes per annum during 2019 and 2020. The pre-production capital associated with opening up Esaase is approximately US$9 million, of which US$7 million is expected to be spent in 2018. A trucking permit has been applied for and is anticipated before the end of 2018.

2018 Guidance and 5 Year Outlook
As announced on March 15, 2018, the Company released its 2018 Guidance and 5-Year Outlook, which is summarized below. This Transaction will enable the AGM to generate strong cash flows to fund its capital requirements over the next three years.

Asanko Gold Mine 100% basis 2018 2019 2020 2021 2022 2023
Ore tonnes mined 000’t 4,300-4,700 7,300 7,560 5,450 6,980 6,400
Average grade mined g/t 1.4 1.4 1.5 1.3 1.5 1.4
Tonnes processed 000’t 4,700-5,000 5,000 5,000 5,000 5,000 5,000
Mill head grade g/t 1.5 1.7 1.8 1.5 1.8 1.7
Gold Production 000’oz 200-220 255 280 220 265 245
AISC1 US$/oz 1,050-1,150 950 810 905 775 880
Total capex US$m 19.5 75.0 100.5 31.5 9.0 18.2

Notes: Based on US$1,250/oz gold and construction of the overland conveyor in 2019/20 

Advisors
In connection with this transaction, BMO Capital Markets and Taurum International acted as financial advisors and McMillan LLP acted as legal counsel to Asanko. Fasken Martineau DuMoulin LLP acted as legal counsel to Gold Fields.

Notes:
1 Non-GAAP Performance Measures
The Company has included certain non-GAAP performance measures in this press release, including all-in sustaining costs per gold ounce (“AISC”). These non-GAAP performance measures do not have any standardized meaning. Accordingly, these performance measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

The Company has adopted the World Gold Council’s guidance for reporting of AISC. AISC include total cash costs, corporate overhead expenses, sustaining capital expenditure, capitalized stripping costs and reclamation cost accretion for each ounce of gold sold.

Qualified Persons
Frederik Fourie, Asanko Senior Mining Engineer (Pr.Eng.) is the Asanko Qualified Person, as defined by Canadian National Instrument 43-101 (Standards of Mineral Disclosure), who has approved the preparation of the mining technical contents of this news release.


Management Conference Call & Webcast Details – 9am ET on Thursday, March 29, 2018
A presentation is available at: www.asanko.com.

Conference Call:
US/Canada Toll Free:   (800) 909-4985
UK Toll Free:                 08004960445
International:                 +1 (212) 231-2929

Webcast:
Please click on the link:   https://cc.callinfo.com/r/144darwuupsw3&eom

Replay:
A recorded playback will be available approximately two hours after the call until April 28, 2018:
US/Canada Toll Free:  800 558 5253
UK Toll Free:                0800 692 0831
International:                +1 416 626 4100
Passcode:                    21886753

About Asanko Gold Inc.
Asanko’s vision is to become a mid-tier gold mining company that maximizes value for all its stakeholders. The Company’s flagship project is the multi-million ounce Asanko Gold Mine located in Ghana, West Africa. Asanko is managed by highly skilled and successful technical, operational and financial professionals. The Company is strongly committed to the highest standards for environmental management, social responsibility, and health and safety for its employees and neighbouring communities.

About Gold Fields Limited
Gold Fields Limited is a globally diversified gold producer with seven operating mines in Australia, Ghana, Peru and South Africa, and a total attributable annual gold-equivalent production of approximately 2.2 million ounces. It has attributable gold Mineral Reserves of around 49 million ounces and gold Mineral Resources of around 104 million ounces. Attributable copper Mineral Reserves total 764 million pounds and Mineral Resources 4,881 million pounds. Gold Fields has a primary listing on the Johannesburg Stock Exchange (JSE) Limited, with secondary listings on the New York Stock Exchange (NYSE) and the Swiss Exchange (SIX).

Forward-Looking and other Cautionary Information
This release includes certain statements that may be deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address the completion of announced agreements including the agreement with Gold Fields, estimated resource quantities, grades and contained metals, possible future mining, exploration and development activities, are forward-looking statements. Although the Company believes the forward-looking statements are based on reasonable assumptions, such statements should not be in any way construed as guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices for metals, the conclusions of detailed feasibility and technical analyses, the timely renewal of key permits, lower than expected grades and quantities of resources, mining rates and recovery rates and the lack of availability of necessary capital, which may not be available to the Company on terms acceptable to it or at all. The Company is subject to the specific risks inherent in the mining business as well as general economic and business conditions. For more information on the Company, Investors should review the Company’s Annual Form 40-F filing with the United States Securities Commission and its home jurisdiction filings that are available at www.sedar.com.

Neither Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note to US Investors Regarding Mineral Reporting Standards:
Asanko has prepared its disclosure in accordance with the requirements of securities laws in effect in Canada, which differ from the requirements of US securities laws. Terms relating to mineral resources in this press release are defined in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects under the guidelines set out in the Canadian Institute of Mining, Metallurgy, and Petroleum Standards on Mineral Resources and Mineral Reserves. The Securities and Exchange Commission (the “SEC”) permits mining companies, in their filings with the SEC, to disclose only those mineral deposits that a company can economically and legally extract or produce. Asanko uses certain terms, such as, “measured mineral resources”, “indicated mineral resources”, “inferred mineral resources” and “probable mineral reserves”, that the SEC does not recognize (these terms may be used in this press release and are included in the public filings of Asanko which have been filed with securities commissions or similar authorities in Canada).

Enquiries:
For further information please visit: www.asanko.com, email: info@asanko.com or contact:

Alex Buck - Manager, Investor and Media Relations
Toll-Free (N.America): 1-855-246-7341
Telephone: +44-7932-740-452
Email: alex.buck@asanko.com

Rob Slater – Executive, Corporate Development and Strategy
Telephone: +27-11-467-2758
Email: rob.slater@asanko.com
Thursday, March 29th, 2018 Uncategorized Comments Off on $AKG to Receive US$185 Million From Gold Fields for 50% Joint Venture

$NETE Recent Analysis, Renewed Outlook, Key Drivers of Growth

NEW YORK, March 29, 2018 — In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Net Element, Inc. (NASDAQ:NETE), McGrath RentCorp (NASDAQ:MGRC), AvalonBay Communities, Inc. (NYSE:AVB), American Tower Corporation (REIT) (NYSE:AMT), Earthstone Energy, Inc. (NYSE:ESTE), and Macerich Company (NYSE:MAC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

NETE DOWNLOAD: http://Fundamental-Markets.com/register/?so=NETE
MGRC DOWNLOAD: http://Fundamental-Markets.com/register/?so=MGRC
AVB DOWNLOAD: http://Fundamental-Markets.com/register/?so=AVB
AMT DOWNLOAD: http://Fundamental-Markets.com/register/?so=AMT
ESTE DOWNLOAD: http://Fundamental-Markets.com/register/?so=ESTE
MAC DOWNLOAD: http://Fundamental-Markets.com/register/?so=MAC

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Net Element, Inc. (NASDAQ:NETE), McGrath RentCorp (NASDAQ:MGRC), AvalonBay Communities, Inc. (NYSE:AVB), American Tower Corporation (REIT) (NYSE:AMT), Earthstone Energy, Inc. (NYSE:ESTE), and Macerich Company (NYSE:MAC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today’s readers below.

—————————————–

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed March 27th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

—————————————–

NET ELEMENT, INC. (NETE) REPORT OVERVIEW

Net Element’s Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Net Element reported revenue of $14.90MM vs $14.01MM (up 6.36%) and basic earnings per share -$0.90 vs -$2.47. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Net Element reported revenue of $54.29MM vs $40.24MM (up 34.92%) and basic earnings per share -$10.33 vs -$23.22. Net Element is expected to report earnings on April 6th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.10.

To read the full Net Element, Inc. (NETE) report, download it here: http://Fundamental-Markets.com/register/?so=NETE

—————————————–

MCGRATH RENTCORP (MGRC) REPORT OVERVIEW

McGrath RentCorp’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, McGrath RentCorp reported revenue of $122.23MM vs $105.28MM (up 16.09%) and basic earnings per share $4.90 vs $0.40 (up 1,125.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, McGrath RentCorp reported revenue of $462.03MM vs $424.08MM (up 8.95%) and basic earnings per share $6.41 vs $1.60 (up 300.63%). McGrath RentCorp is expected to report earnings on May 1st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $2.91 and is expected to report on February 26th, 2019.

To read the full McGrath RentCorp (MGRC) report, download it here: http://Fundamental-Markets.com/register/?so=MGRC

—————————————–

AVALONBAY COMMUNITIES, INC. (AVB) REPORT OVERVIEW

AvalonBay Communities’ Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, AvalonBay Communities reported revenue of $555.29MM vs $518.24MM (up 7.15%) and basic earnings per share $1.71 vs $1.76 (down 2.84%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, AvalonBay Communities reported revenue of $2,158.63MM vs $2,045.26MM (up 5.54%) and basic earnings per share $6.36 vs $7.53 (down 15.54%). AvalonBay Communities is expected to report earnings on April 25th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $2.09. The estimated EPS forecast for the next fiscal year is $9.32 and is expected to report on January 30th, 2019.

To read the full AvalonBay Communities, Inc. (AVB) report, download it here: http://Fundamental-Markets.com/register/?so=AVB

—————————————–

AMERICAN TOWER CORPORATION (REIT) (AMT) REPORT OVERVIEW

American Tower Corporation (REIT)’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, American Tower Corporation (REIT) reported revenue of $1,704.46MM vs $1,539.58MM (up 10.71%) and basic earnings per share $0.50 vs $0.47 (up 6.38%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, American Tower Corporation (REIT) reported revenue of $6,663.90MM vs $5,785.70MM (up 15.18%) and basic earnings per share $2.69 vs $2.00 (up 34.50%). American Tower Corporation (REIT) is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.58. The estimated EPS forecast for the next fiscal year is $8.01 and is expected to report on February 26th, 2019.

To read the full American Tower Corporation (REIT) (AMT) report, download it here: http://Fundamental-Markets.com/register/?so=AMT

—————————————–

EARTHSTONE ENERGY, INC. (ESTE) REPORT OVERVIEW

Earthstone Energy’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Earthstone Energy reported revenue of $35.68MM vs $15.15MM (up 135.45%) and basic earnings per share $0.12 vs -$1.60. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Earthstone Energy reported revenue of $108.08MM vs $42.27MM (up 155.69%) and basic earnings per share -$0.53 vs -$2.92. Earthstone Energy is expected to report earnings on May 14th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.06. The estimated EPS forecast for the next fiscal year is $1.16 and is expected to report on March 13th, 2019.

To read the full Earthstone Energy, Inc. (ESTE) report, download it here: http://Fundamental-Markets.com/register/?so=ESTE

—————————————–

MACERICH COMPANY (MAC) REPORT OVERVIEW

Macerich’s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Macerich reported revenue of $256.74MM vs $272.00MM (down 5.61%) and basic earnings per share $0.23 vs $0.35 (down 34.29%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Macerich reported revenue of $993.66MM vs $1,041.27MM (down 4.57%) and basic earnings per share $1.02 vs $3.52 (down 71.02%). Macerich is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.87. The estimated EPS forecast for the next fiscal year is $4.15 and is expected to report on February 4th, 2019.

To read the full Macerich Company (MAC) report, download it here: http://Fundamental-Markets.com/register/?so=MAC

—————————————–

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world’s leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets’ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets’ oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Fundamental Markets’ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets’ Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Thursday, March 29th, 2018 Uncategorized Comments Off on $NETE Recent Analysis, Renewed Outlook, Key Drivers of Growth

$PBIO to Discuss Fourth Quarter and FY2017 Financial Results

SOUTH EASTON, MA / March 29, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2017 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone or via a link on the Company’s website approximately one day after the teleconference).

The teleconference will include a Company presentation followed by a question & answer period.

Date: Tuesday, April 3, 2018 Time: 4:30 PM Eastern Daylight Time (EDT)

To attend this teleconference live by telephone:

Dial-in: (877) 407-8031 (North America); (201) 689-8031 (International)

Verbal Passcode (for the operator): PBI Fourth Quarter and FY2017 Financial Call & Business Update

For those unable to participate in the live teleconference, a replay will be available beginning Wednesday, April 4, 2018. The replay will be accessible via telephone and the Company’s website for 30 days.

Replay Number: (877) 481-4010 (North America); (919) 882-2331 (Int’l); Replay ID Number: 27377

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

For more information about PBI and this press release, please click on the following link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President & CEO (T) 508-230-1828

Thursday, March 29th, 2018 Uncategorized Comments Off on $PBIO to Discuss Fourth Quarter and FY2017 Financial Results

$CHOOF Countdown to Canada’s Recreational Cannabis Industry Enters Retail Territory

March 29, 2018

NetworkNewsWire Editorial Coverage: Recreational cannabis will soon be legal in Canada for adults, but selling and buying the pungent herb won’t be as simple as some presume it will be. Regulations governing the cultivation, production, packaging and sale of cannabis are still being refined as Canadian lawmakers at different levels of government tackle unique differences between provinces and local jurisdictions. One thing is certain, however: a cannabis retail explosion is coming, and cannabis companies ready for the surge will reap the benefits when Canada’s recreational marketplace officially opens for business. Cannabis retail brand Choom™ Holdings, Inc. (CSE: CHOO) (OTCQB: CHOOF) (CHOOF Profile) is preparing to meet the demands of this market with a strategic blend of product and consumer experience, while Hiku Brands Company. Ltd. (CSE: HIKU) (OTC: DJACF) (DJACF Profile) steadies itself as a lifestyle cannabis brand. Canada’s top cultivators, Canopy Growth Corporation (TSX: WEED) (OTC: TWMJF); Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF); and ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) (ABCCF Profile) are also exploring getting in the game.

Economic Boost

Close to 5 million Canadians aged 15 to 64 spent an estimated $5.7 billion on cannabis in 2017, according to a Cannabis Economic Account issued by Statistics Canada (http://nnw.fm/m1AnR). That’s nearly $1,200 per cannabis consumer, although the report does caution that the data is an estimate. Canada’s foray into legalized recreation cannabis will bring more concrete numbers, especially once the nation’s projected $450 million in annual cannabis tax revenue begins to roll in, and the nation’s provinces get a 75 percent share of the loot (http://nnw.fm/EhMe6).

Retail Me Now

Estimates vary as to how much revenue is out there when it comes to legalized cannabis. A 2016 report (http://nnw.fm/R5Csq) from the Canadian Parliamentary Budget Officer estimated a $5.5 billion to $5.8 billion annual retail market while a far more enthusiastic Deloitte study predicted an industry generating more than $22 billion a year (http://nnw.fm/dR0OF). Either way, that translates into an undeniable demand for cannabis. For Choom Holdings (CSE: CHOO) (OTCQB: CHOOF) and its experienced team of cannabis curators, Canada’s upcoming “green rush” presents an incredible opportunity to build premium brand loyalty through the company’s unique retail strategy.

Cannabis Connoisseur

A heady amount of the laid-back spirit of Hawaii is channeled into Choom™ and its unofficial history. Choom was inspired by the Choom Gang, a group of buddies living in Honolulu during the 1970s who loved to relax with “choom,” the local’s term for marijuana. That Choom “vibe” flows throughout the corporate structure today with the company’s commitment to the principle of keeping and maintaining “good times and good friends.”

One of the best ways to do that may be by cultivating naturally grown, premium cannabis that provides an elevated experience for the consumer, then sharing that business model with entrepreneurs in a unique Choom Partner Program (http://nnw.fm/gYs2q). This chain of branded retail cannabis dispensaries will find homes in Canadian jurisdictions where recreational cannabis is legalized for retail sale.

License to Sell

The government in British Columbia, where Choom is headquartered, has issued several guidelines for individuals and businesses seeking a recreational cannabis retail license. Importantly, while the government said the B.C. Liquor Distribution Branch would be the wholesale distributor of nonmedical cannabis, it would not impose a quota on the number of licenses issued for private retail outlets (http://nnw.fm/4PKfP). That’s good news for individuals and companies seeking an entry into the booming cannabis sector.

Fittingly, Choom recently announced it has signed the first agreement in its retail investor program with a consortium known as the Thompson Okanagan Choom Group. Comprised of local investors and business partners, the consortium has secured the exclusive territory rights to open multiple Choom-branded retail dispensaries in the gorgeous Thompson-Okanagan region of British Columbia (http://nnw.fm/4kJMd).

Each Choom retail store is designed with a clean and modern mindset geared to help customers feel at home and enjoy the “aloha” experience. The company’s partner program includes support and access to the expertise and partnerships of the Choom brand and its nimble, adaptive business model. As experienced curators of cannabis, Choom will use its products and services to grow and adapt to the changing cannabis landscape, which is likely a necessary component in Canada’s current regulatory climate.

But Wait, There’s More

While it appears the distribution of wholesale cannabis and online sales will be largely government controlled, provinces and territories have opted for one of three retail models for over-the-counter sales: private, public or a hybrid of the two (http://nnw.fm/Nij0p). The Saskatchewan government, for instance, announced in January that the Saskatchewan Liquor and Gaming Authority would be tasked with issuing about 60 retail permits to private stores located in roughly 40 municipalities and First Nations across the province (http://nnw.fm/w4fCh). Ontario, on the other hand, will only allow cannabis to be sold by the Ontario Cannabis Retail Corporation, a subsidiary of the Liquor Control Board of Ontario (http://nnw.fm/qyg7E).

Cultivating an Experience

Choom has acquired International Tungsten, Inc. (ITI), a late-stage applicant for an ACMPR (Access to Cannabis for Medical Purposes Regulations) cultivation license through its subsidiary, Specialty Medijuana Products Inc. (SMP) (http://nnw.fm/p2Tax). SMP, whose cultivation facility is located in British Columbia, expects to receive its Health Canada cultivation license within the next few weeks, followed by a sales license by the third quarter of 2018. Benefits of this acquisition are significant, moving Choom closer to scaling up cultivation capacity and reaping its first cannabis harvest under this new resource (http://nnw.fm/5A3qi).

Choom already has security clearance with one ACMPR through its subsidiary Medi-CanHealth Solutions Ltd., which is currently in the detailed review stage. Growth plans include a Phase 1 cannabis production facility capable of producing approximately 660 kg of dried cannabis per year, along with expansion plans to increase production to 1,500 kg/year. A second ACMPR application, also in the readiness stage, is located on Vancouver Island with the potential to eventually produce 900 kg/year.

Earlier this week (http://nnw.fm/35Iml), Choom expanded its portfolio with a Letter of Intent to acquire advanced-stage cannabis production license applicant Flower Power and its wholly owned subsidiary, High Way 10 Cannabis Pharms Inc. Located in Southern Saskatchewan, High Way 10 has a 16,000-square-foot facility that will be capable of producing roughly 1,500 kg of dried cannabis annually. In addition to room for additional expansion, Flower Power is advancing its retail store strategy across the country to create a consumer experience that elevates and evolves the traditional dispensary vibe. It intends to have a hybrid of corporately owned and franchised dispensaries, subject to the formal legalization of recreational cannabis by Health Canada and provincial and municipal guidelines.

Complementary to Choom’s corporate vision, this acquisition marks Choom’s fourth advanced-stage applicant and demonstrates the company’s commitment to scale up its operations to meet the demands of the Canadian recreational market.

Other Players

Hiku Brands (CSE: HIKU) (OTC: DJACF) just received one of four master retail licenses in Manitoba’s highly competitive Request for Proposal process, giving Hiku the right to operate retail cannabis stores in the province (http://nnw.fm/jnd7T). The license, awarded to Hiku’s wholly owned subsidiary, Tokyo Smoke, represents what company CEO Alan Gertner called “a validation of our business model and vision of creating an unsurpassed retail experience for cannabis consumers.”

Through its subsidiaries, Canopy Growth (TSX: WEED) (OTC: TWMJF) is a Canadian licensed producer of medical marijuana operating Tweed Main Street Shops in communities throughout southern Ontario (http://nnw.fm/Er6RT). Tweed Main Street has deep roots in the cannabis community, offering Canada’s most “relied upon brands” under one roof. The company’s medical cannabis orders are sent directly to the client after being processed the same day 99 percent of the time, with an average wait call time of less than two minutes.

Aurora Cannabis (TSX: ACB) (OTCQX: ACBFF) is taking a different retail approach by proposing to create medical cannabis retail outlets by converting existing liquor store retail locations in the province of Alberta (http://nnw.fm/XLeK6). Aurora Cannabis, which cultivates, produces and sells medical cannabis, plans to establish “a new customer experience for adult consumers.” The company recently entered into an agreement to become an online medical cannabis supplier for Shoppers Drug Mart, subject to Health Canada’s approval of an application by Shoppers to be a licensed producer (http://nnw.fm/1o8lW).

ABcann Global (TSX-V: ABCN) (OTCQB: ABCCF) has signed an agreement with Choom to market ABcann’s cannabis products through Choom’s branded retail platform. As part of the deal, ABcann Global is making a strategic $4 million investment into Choom, signaling a strong commitment and belief in the company’s unique, customized approach to the recreational cannabis market (http://nnw.fm/PZto7). As one of the earliest licensed medical marijuana producers in Canada, ABcann has five years of operating experience in the medical marijuana space. The company currently owns and operates a fully functioning 14,500-square-foot facility in Napanee, Ontario, as well as 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

Preparation Counts

Scrambling or playing catch-up is never the best business advice, as any successful entrepreneur will tell you. But being able to use that kind of nimble, quick-thinking, planning-ahead ability should bode well for Canada’s cannabis producers and retailers as summer 2018 looms large on the horizon. Companies are lining up financing, expanding production facilities, designing retail spaces and shoring up supplies to meet the expected demand as Canada begins legalizing recreational cannabis for adults 19 years old and over. As Alexander Graham Bell so famously said, “Before anything else, preparation is the key to success.”

For more information on Choom Holdings, please visit Choom Holdings (CSE: CHOO) (OTCQB: CHOOF).

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Thursday, March 29th, 2018 Uncategorized Comments Off on $CHOOF Countdown to Canada’s Recreational Cannabis Industry Enters Retail Territory

$ETST Expands Presence in Blossoming Hemp-Based CBD Market

March 9, 2018

  • Agreement with Mr. Checkout will significantly strengthen the company’s product distribution network
  • Human trials launched evaluating CBD-based therapy for opioid addiction
  • Application made to uplist to OTCQB in early 2018, attracting more investment

The worldwide cannabidiol (CBD) oil market, which includes products derived from both marijuana and hemp, is projected to grow at a CAGR of more than 39 percent through 2021. The health benefits of CBD oil are the major driver for growth in this market, with global demand steadily on the rise in recent years. Hemp-based CBD oil products in particular are more popular, as they have a lower concentration of psychoactive compound tetrahydrocannabinol (THC) than those derived from marijuana, therefore not requiring a medical prescription (http://cnw.fm/kaL9i). Earth Science Tech, Inc. (OTC: ETST) is one of the companies that is focused on the development of hemp-based CBD products and has taken a number of steps recently to enlarge its presence in this market sector.

Following a revamp of its CBD product line, Earth Science Tech announced on February 13, 2018, that it had concluded an agreement with Mr. Checkout for the distribution of its products via major retailers and stores across the United States. This agreement will strengthen the company’s distribution network, which currently has 10 active representatives targeting distribution to health food stores and clinics. Mr. Checkout is a national group of independent distributors of products to over 60 major retailers and 55,000 stores. It will market ETST’s product line to major retailers such as Walmart, Walgreens and Target.

Earth Science Tech is a biotechnology company focused on the research and development of hemp-based CBD products for the pharmaceutical and nutraceutical industries. It also has a focus on the development of diagnostic tools and medical devices. On February 28, 2018, the company announced that it had finalized plans to conduct human trials on its new CBD-based formulation that targets opioid addiction (http://cnw.fm/rNnQ0). These trials will assess the efficacy of the combination of hemp-based CBD oil with an essential mineral element. Currently, the sole therapy for this condition is a monotherapy based on an essential mineral element. ETST’s formulation is expected to increase the potency and improve the outcome of this therapy.

The company operates through three wholly owned subsidiaries:

  • Cannabis Therapeutics, Inc. which develops leading edge, cannabinoid-based products for the pharmaceutical and nutraceutical sectors;
  • KannaBidioiD which is focused more on developing products for the recreational use of cannabis, including edibles, vapes and eLiquids;
  • Earth Science Pharma, Inc., which develops medical devices and low-cost, noninvasive diagnostic tools, as well as testing processes and vaccines for sexually transmitted diseases.

Cannabis Therapeutics is in the development stage of two CBD-based pharmaceutical drugs and three CBD-based nutraceutical products. These will target a variety of ailments, including depression, anxiety, breast cancer and fatty liver disease. In October 2017, Earth Science Tech announced a collaboration with Clinique SIDA Amité to conduct a mini-trial on its MSN-2 device for the detection of Chlamydia. ETST has also acquired Canna Inno Laboratories Inc., based in Montreal, Canada, which will give the company the opportunity to expand into Canada and gain access to local government grants for pharmaceutical industry innovation.

Earth Science Tech expects to uplist to the OTCQB Venture Exchange in early 2018, which it believes will attract well-funded institutional investors. These recent developments are likely to increase company growth and enlarge Earth Science Tech’s presence in the cannabis industry.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Thursday, March 29th, 2018 Uncategorized Comments Off on $ETST Expands Presence in Blossoming Hemp-Based CBD Market

$CLWT To Sell Its Stake in Zhejiang Jiahuan Electronics

HONG KONG, March 28, 2018 — Euro Tech Holdings Company Limited (Nasdaq: CLWT) today announced that it has recently signed an Equity Transfer Agreement (the “Agreement”) to sell its 20% equity stake of Zhejiang Jiahuan Electronics Co., Ltd. (“Jia Huan”) to an individual, who is the wife of the holder of the remaining 80% equity stake of Jia Huan, for a purchase price of RMB$31,312,500. The completion of the transaction is subject to completion of all closing formalities, including the need to obtain approval and registration with the relevant governmental authorities and the receipt of payment from the Purchaser. The Company’s decision to enter into the Agreement and dispose of its equity stake in Jia Huan was based upon the intention of Jia Huan’s major shareholder to diversify the business of Jia Huan into new areas that are unrelated to its and the Company’s existing activities.

About Jia Huan

Zhejiang Jia Huan Electronic Co. Ltd. in Zhejiang, China (“Jia Huan”), an established company, has been in business since 1969. 95% of Jia Huan’s business is related to air pollution control and less than 5% is for water and wastewater treatment. Jia Huan designs and manufactures automatic control systems and electric voltage control equipment for electrostatic precipitators which are major air purification equipment for power plants, cement plants and incinerators to remove and collect dust and pollutants from the exhaust stacks. The Company held the 20% equity in Jia Huan since January 2008.

Forward Looking Statements

Certain statements in this news release regarding the Company’s expectations, estimates, present view of circumstances or events, and statements containing words such as estimates, anticipates, intends, or expects, or words of similar import, constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements indicate uncertainty and the Company can give no assurance with regard to actual outcomes. Specific risk factors may include, without limitation, having the Company’s offices and operations situated in Hong Kong and mainland China, doing business in China, competing with Chinese manufactured products, competing with the Company’s own suppliers, dependence on vendors, and lack of long term written agreements with suppliers and customers, development of new products, entering new markets, possible downturns in business conditions, increased competition, loss of significant customers, availability of qualified personnel, negotiating definitive agreements, new marketing efforts and the timely development of resources. See the “Risk Factor” discussions in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 20-F for its fiscal year ended December 31, 2016.

Wednesday, March 28th, 2018 Uncategorized Comments Off on $CLWT To Sell Its Stake in Zhejiang Jiahuan Electronics

$IVAC oDLC® to Begin Shipping on Top 3 Cellphone Maker’s Flagship Smartphone

Scratch-Resistant Coating to Protect Selected Decorative Back Cover Glass Options

Intevac, Inc. (Nasdaq: IVAC), a leading supplier of thin-film processing systems, today formally announced that its market-leading thin-film technology, oDLC® (optical Diamond-Like-Carbon), is being applied to protect selected decorative back cover glass options for the recently-launched flagship smartphone of a Top 3 Cellphone maker. oDLC is an optically-transparent, protective thin-film coating, which provides significant improvements in the scratch and wear resistance of display cover panels and film coating stacks on the surfaces of all types of mobile electronic devices, as well as point-of-sale and automotive infotainment systems.

Backside cover glass for mobile phones is a recent phenomenon that is addressing a rapidly-growing portion of the high-end smartphone market. While most early adopters of backside cover glass have opted to achieve color variations by coating the inside of the glass, the flagship smartphone launched this week is the first major phone to have decorative back cover glass options where the colors are deposited on the outside of the glass, making them exceptionally vibrant and striking. Intevac’s oDLC protects these decorative coatings from scratches and wear arising out of daily use.

Truly Opto-electronics (Shanwei City, China), a major supplier of cover glass and touch panel technologies to mobile electronics manufacturers and owner of multiple INTEVAC VERTEX® systems, went through an intensive testing process lasting several months to ensure that oDLC met the stringent specifications laid out by the technical team at the Top 3 Cellphone maker.

“Truly Opto-electronics’ Engineering team thoroughly qualified Intevac’s oDLC protective coating technology with the decorative coating on the backside glass that went into this flagship smartphone from a Top 3 Cellphone maker. This production order is a significant validation of our coating capabilities meeting top-tier customer requirements,” commented Mr. Li, Managing Director of Truly Opto-electronics. “We believe that oDLC offers superior film protection at a low cost to customers. We are working with other customers on positioning oDLC for several different production applications.”

“Intevac is excited about our strong partnership with Truly, which has led to the adoption of oDLC by a leading cellphone maker on their flagship smartphone, and we look forward to leveraging this design win to drive adoption of oDLC at multiple mobile phone customers across a range of applications,” added Jay Cho, Executive Vice President and General Manager of Intevac’s Thin-Film Equipment business.

The thin-film equipment that enables the oDLC solution is the INTEVAC VERTEX multi-stage physical vapor deposition (PVD) system. The VERTEX PVD system deposits the oDLC thin-film coating vertically and at the low process temperatures required for display cover panel processing. The VERTEX is an optimal production solution for small individualized substrates, achieving the highest level of throughput at the lowest possible cost.

About Intevac

Intevac was founded in 1991 and has two businesses: Thin-film Equipment and Photonics.

In our Thin-film Equipment business, we are a leader in the design and development of high-productivity, thin-film processing systems. Our production-proven platforms are designed for high-volume manufacturing of substrates with precise thin film properties, such as the hard drive media, display cover panel, and solar photovoltaic markets we serve currently.

In our Photonics business, we are a recognized leading developer of advanced high-sensitivity digital sensors, cameras and systems that primarily serve the defense industry. We are the provider of integrated digital imaging systems for most U.S. military night vision programs.

For more information call 408-986-9888, or visit the Company’s website at www.intevac.com.

 

Intevac, Inc.
James Moniz, 408-986-9888
Chief Financial Officer
or
Claire McAdams, 530-265-9899
Investor Relations

Wednesday, March 28th, 2018 Uncategorized Comments Off on $IVAC oDLC® to Begin Shipping on Top 3 Cellphone Maker’s Flagship Smartphone

$NAUH Schedules Fiscal 2018 Financial Results Release

RAPID CITY, S.D., March 28, 2018 — National American University Holdings, Inc. (the “Company”) (NASDAQ:NAUH), which through its wholly owned subsidiary operates National American University, a regionally accredited, proprietary, multi-location institution of higher learning, today announced that it intends to release financial results for its fiscal 2018 third quarter and nine months ended February 28, 2018, after the closing of the stock market on Wednesday, April 4, 2018. The Company will then discuss those results in a conference call on Thursday, April 5, 2018, at 11:00 a.m. ET.

The dial-in numbers are:
(877) 407-9078 (U.S.)
(201) 493-6745 (International)

Accompanying Slide Presentation and Webcast
The Company will have an accompanying slide presentation available in PDF format at the “Investor Relations” section of the NAU website at www.national.edu. The presentation will be made available 30 minutes prior to the conference call.  In addition, the call will be simultaneously webcast over the Internet via the “Investor Relations” section of the NAU website or by clicking on the conference call link: http://national.equisolvewebcast.com/q3-2018. The webcast will be archived and accessible for approximately 30 days.

About National American University Holdings, Inc.
National American University Holdings, Inc., through its wholly owned subsidiary, operates National American University (“NAU”), a regionally accredited, proprietary, multi-location institution of higher learning offering associate, bachelor’s, master’s, and doctoral degree programs in technical and professional disciplines. Accredited by the Higher Learning Commission, NAU has been providing technical and professional career education since 1941. NAU opened its first location in Rapid City, South Dakota, and has since grown to multiple locations in several U.S. states. In 1998, NAU began offering online courses. Today, NAU offers degree programs in traditional, online, and hybrid formats, which provide students increased flexibility to take courses at times and places convenient to their busy lifestyles.

 

Contact Information:
National American University Holdings, Inc.
Dr. Ronald Shape
605-721-5220
rshape@national.edu
Investor Relations Counsel
The Equity Group Inc.
Carolyne Y. Sohn Adam Prior
415-568-2255 212-836-9606
csohn@equityny.com aprior@equityny.com
Wednesday, March 28th, 2018 Uncategorized Comments Off on $NAUH Schedules Fiscal 2018 Financial Results Release

$ETST Sees Explosive Sales Growth in 2018

March 28, 2018

  • Nickolas Tabraue, ETST president, gives up COO position to Gagan Hunter, noting that the move completes the ‘puzzle’ to drive company to new heights in alternative medicine market
  • Biotech company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing high-grade, industrial hemp cannabidiol (CBD)
  • Company projects a breakout year in 2018, in part due to revamping of its executive team and introducing a new marketing strategy for its repositioned and repackaged line of industrial hemp products

Earth Science Tech, Inc. (OTC: ETST), by naming Gagan Hunter as its new COO, has completed a transition, positioning the company to reach ‘new heights’ with a new team in place and a revamped marketing strategy for its industrial hemp-sourced line as a cannabinoid complex, as detailed by Nickolas Tabraue, company director and president, in a recent news release (http://cnw.fm/i0XFy). Tabraue, who served as COO prior to the appointment of Hunter, said that ETST has positioned itself for ‘explosive sales growth’ in 2018 (http://cnw.fm/JxpO7).

Hunter said that he looks forward to strengthening the company’s operations. He has 20 years of experience in the natural products industry, joining a number of seasoned additions to the ETST team. Earlier, the company put in place the team of Jill Buzan as chief sales officer, Sergio Castillo as chief marketing officer, and Gabriel Aviles as chief learning officer (http://cnw.fm/2vgQE).

Tabraue added, “I feel that we finally have the last piece of our puzzle in place to take ETST to new heights. Gagan has many great ideas to implement that will help the company work more efficiently and with greater organization. We now have every major role managed by passionate, likeminded individuals to truly make ETST an innovative, trusted brand in the alternative medicine space.”

Earth Science Tech is an innovative biotech company based in Doral, Florida. It markets a repositioned and repackaged line of High Grade Full Spectrum cannabidiol (CBD) oil products.  Focused on manufacturing and marketing cannabinoid products to the pharmaceutical and nutraceutical markets, it also conducts R&D for low-cost, non-invasive medical devices.

The company holds three wholly owned subsidiaries, including:

  • Earth Science Pharmaceutical, which develops medical diagnostic tools and vaccines;
  • Cannabis Therapeutics, an emerging biotechnology company; and
  • KannaBidioiD, which is focused on cannabidiol production and distribution in the recreational space.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Wednesday, March 28th, 2018 Uncategorized Comments Off on $ETST Sees Explosive Sales Growth in 2018

$ATNX to Present at the 17th Annual Needham Healthcare Conference

BUFFALO, N.Y., March 27, 2018 — Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Dr. Simon Pedder, Chief Business and Strategy Officer, will present at the 17th Annual Needham Healthcare Conference in New York City on Tuesday, March 27, 2018 at 2:00 pm EDT.

The presentation will be webcasted, and can be accessed at the Investor Relations section of the Company’s website, located at www.athenex.com. An archive will be available on this website until April 27, 2018.

About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.

CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.

Tuesday, March 27th, 2018 Uncategorized Comments Off on $ATNX to Present at the 17th Annual Needham Healthcare Conference

$PVOTF Named to the CSE25 Index

March 27, 2018

  • Pivot Pharmaceuticals attains prestigious CSE25 status
  • Recent acquisitions have extended the company’s portfolio in the cannabis space
  • Numerous pharmaceutical and nutraceutical products in development pipeline

Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) announced on March 19, 2018, that it has been named to the CSE25 Index (http://cnw.fm/g1qK7). CSE25 is a conglomerate of the 25 largest companies by market capitalization listed on the Canadian Securities Exchange. This achievement adds to Pivot Pharmaceuticals’ status as a constituent of the CSE Composite Index, which provides a distinctly different risk/return profile than the broad Canadian equity market.

“With an impressive pipeline of bio-cannabis products, a strong intellectual property portfolio of formulation and delivery technologies, and the expected addition of ACMPR licensed Agro-Biotech, we are proud to be recognized as leaders on the Canadian Securities Exchange through our inclusion in the CSE25 Index,” Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated in the news release. “Being among the top 25 performers on the exchange validates our business strategy to become a vertically integrated health and wellness company with a rapidly expanding international presence. With all of the exciting opportunities ahead of us, we believe we will remain a consistent part of the CSE25 Index for years to come as we continue to drive shareholder value.”

In February 2018, Pivot Pharmaceuticals entered into a letter of intent for the acquisition of Agro-Biotech Inc., a cannabis cultivator located in Quebec. Agro-Biotech received its producer’s license on January 12, 2018. On completion of the proposed acquisition, Pivot will be able to conduct research and development and store cannabis derivatives not currently covered under ACMPR regulations. The company will also be in a position to process natural health products and export cannabis oils and concentrates to international markets, once it receives an export permit.

The company’s recent acquisitions also include Thrudermic, LLC, a company based in North Carolina that has developed a transdermal, lipid-based nano-dispersion technology for cannabinoid delivery. Pivot also acquired ERS Holdings, LLC in February 2018, a California-based company that holds patents for the production of powderized cannabis oil that can be added to beverages and baked goods.

Pivot Pharmaceuticals is a Vancouver-based biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals through proprietary drug delivery technologies via medical cannabis product division Pivot Green Stream Health Solutions (“PGS”). In early February 2018, the company announced that it had filed three provisional patents for cannabinoid-based product delivery technologies with the U.S. Patent Office. These are for its innovative transdermal nanotechnology, inhalation and mucus topical delivery platforms. Its BiPhasix™ Transdermal Drug Delivery technology has been tested in clinical trials approved by both the FDA and EMA. This delivery platform provides significant advantages over oral delivery technologies.

Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://cnw.fm/32ENj). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Tuesday, March 27th, 2018 Uncategorized Comments Off on $PVOTF Named to the CSE25 Index

$NETE Strong Management Team Driving Organic Growth, Blockchain Developments

March 27, 2018

  • Leadership team leveraging years of experience to sustainably meet company’s goals
  • Organic growth, single payment processing platform that integrates any payment ecosystem among top goals for 2018 and beyond
  • Payment processing industry set to reach $2.2 trillion by 2021

On the heels of a remarkable performance in 2017, which ended with the strongest balance sheet in the company’s history and a $7.55 million investment, global technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) is targeting sustained organic growth across all sectors, as well as significant advancements in blockchain developments. With a highly experienced and committed management team at the helm, bringing a unique blend of vision, leadership and creative energy, the company looks all but set to achieve its goals for 2018 and beyond.

The overall vision, strategy and execution of Net Element’s mission are in the hands of its CEO and director, Oleg Firer. Recognized as one of the top entrepreneurs in Florida and one of the most influential people in Miami by publications such as Business Leader Magazine, Forbes and Poder Magazine, Firer served as executive chairman of Unified Payments before taking his current position. During his tenure, Unified Payments was ranked as the fastest-growing company in 2012 by Inc. Magazine, having grown its revenues by 23,646 percent over a three-year period. Unified Payments, which provides various payment processing services, including mobile payment acceptance to small- and medium-sized merchants, was acquired by Net Element in April 2013. Firer is leveraging his experience and skills to help drive Net Element’s sustained growth and achieve the group’s long-term goal of creating a single, international processing platform.

The company’s chief technology officer, Andrey Krotov, is an experienced software engineer originating from Russia. He first joined Net Element as a senior software developer in early 2011 but soon became head of Net Element Russia’s development department, where he remained until March 2014, when he took his current management position. He previously worked as a software engineer and senior software engineer with software development companies such as Interactive Tribe GmbH and Artsofte. With a master’s degree from Russia’s Ural State Technical University, Krotov has focused throughout his career on the creation of proprietary intellectual property and the management of both local and outsourced software developing teams. He will use his expertise to continue overseeing and coordinating Net Element’s product development efforts.

With a BS in accounting from Florida State University and vast experience in providing financial and accounting services to a number of companies, Jonathan New has served as chief financial officer of Net Element since 2008. Before joining Net Element, he provided auditing, reporting and corporate accounting services to different public companies. He is a member of the American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants.

Net Element’s chief legal officer and secretary, Steven Wolberg, is an experienced attorney who has been practicing for years in both the United States and South Africa. Wolberg is a member of the Massachusetts Bar Association; he received his bachelor of laws from the University of Witwatersrand in Johannesburg and his juris doctorate from the New England School of Law in Boston. He has served as chief legal officer of Net Element since 2013, before which he served in various capacities with Acies Corporation, a financial services and payment processing company, and several other firms.

As the global payments industry continues to thrive and is expected to surpass $2.2 trillion dollars in volume by 2021 (http://nnw.fm/49lVU), Net Element is set to strengthen its position as a leading developer and provider of innovative payment solutions. Supporting electronic payments acceptance in a multi-channel environment, from mobile devices to blockchain, e-commerce and point-of-sale, the company remains focused on continuing its organic growth, developing innovative payment solutions, especially in the field of blockchain and, ultimately, creating a single onboarding and transaction processing platform that will accommodate both local and international payment ecosystems.

For more information, visit the company’s website at www.NetElement.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Tuesday, March 27th, 2018 Uncategorized Comments Off on $NETE Strong Management Team Driving Organic Growth, Blockchain Developments

$VRNA Positive Top-Line Data Phase 2b Clinical of RPL554 in COPD

Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels  

Clinically relevant secondary endpoints were also met, including statistically significant, progressive improvements in COPD symptoms

RPL554 was well tolerated at all dose levels in this four week 400 patient study

Management to hold conference call and webcast today at 8 am EDT / 1 pm BST

LONDON, March 26, 2018 —  Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today positive top-line data from its Phase 2b study evaluating RPL554, a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 with bronchodilator and anti-inflammatory properties, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).

The study met its primary endpoint, with RPL554 producing a clinically and statistically significant improvement in peak forced expiratory volume in one second (FEV1) at four weeks in patients with moderate-to-severe COPD compared to placebo. Furthermore, the peak FEV1 was significantly improved at all time points over the four weeks of dosing. Secondary endpoints measuring 12 hour average FEV1, COPD symptoms and Quality of Life were also met and support the potential clinical benefits of RPL554 for the treatment of COPD.

The four-week, double-blind, placebo-controlled, parallel group, Phase 2b multicenter European study performed in the out-patient setting evaluated the efficacy, safety, and dose-response of nebulized RPL554 administered twice-daily as a maintenance treatment for COPD in 403 patients with moderate-to-severe COPD. There were four dosing arms of RPL554 (0.75 mg, 1.5 mg, 3.0 mg and 6.0 mg) in the study in addition to placebo and patients were required to withhold use of regular long-acting bronchodilator therapy for the duration of the study.

Highlights

Primary endpoint:

  • RPL554 met the primary endpoint at all doses, showing a statistically significant difference vs. placebo (p<0.001) with absolute changes from baseline >200mL in peak FEV1 after 4 weeks of dosing. No minimum effective dose could be determined.
  • This peak bronchodilator effect was observed at the first dose and was sustained over four weeks (p<0.001).

Secondary endpoints include:

  • Statistically significant improvements in average FEV1 over 12 hours were observed at all doses after the first administration, and this effect was sustained over four weeks.
  • This study did not demonstrate consistent improvements in trough FEV1.
  • Recording of daily COPD symptoms, using E-RS (EXACT-PRO)1, demonstrated a significant improvement in total COPD symptoms (p<0.002), including improvements in breathlessness (p<0.02), chest symptoms (p<0.02), and cough and sputum (p<0.02).
  • Strong trend of improvement in SGRQ-C2 of >2.5 units was observed in all dose groups after four weeks.
  • Patients’ Global Impression of Change3 indicates that patients felt better on RPL554 compared to placebo (p<0.01).
  • RPL554 was well tolerated at all doses with an adverse event profile similar to placebo.

Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, University of Manchester, a Lead Investigator in the study, commented, “The results from this relatively large and well-designed study are very encouraging and clinically meaningful. The large and sustained improvement in lung function and reduction in COPD symptoms, including reduction in breathlessness, are particularly noteworthy. When coupled with the drug’s unique mechanism of action, these data underline the potential for RPL554 as a new complementary treatment for patients with this progressive and debilitating disease, where there remains a high unmet medical need.’’

Verona Pharma’s CMO, Ken Newman, M.D. said, “I am delighted that we met the primary endpoint of peak FEV1, confirming the strong bronchodilator effect of RPL554 in COPD patients. The clinically meaningful improvement in daily reported COPD symptom scores in all sub-domains, that continued to improve over the four week treatment period, is particularly exciting and promising.’’

“These results are very encouraging and strongly support the progression of RPL554 into later stage development as an inhaled treatment for COPD patients”, said Jan-Anders Karlsson, PhD., CEO of Verona Pharma. “The future clinical development and the positioning of this novel treatment will be informed by these data as well as by the outcome of the clinical study as an add-on to established combination therapies planned to start this year, and our ongoing market research”.

In previous clinical trials, RPL554 has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva®), compared with such bronchodilators administered as a single agent. In addition, RPL554 has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. In these studies, RPL554 has been well tolerated. RPL554 also has a favorable safety and tolerability profile, having been administered in more than 730 subjects in 12 clinical trials.

1 E-RS (EXACT-PRO) – a recognized patient-reported outcome measure for use in clinical studies of COPD.

2 SGRQ-C – St. George’s Respiratory Questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with COPD.

3 Patients’ Global Impression of Change – a scale reflecting the patient’s belief about the efficacy of treatment.

Conference Call
Verona Pharma will host an investment community conference call today at 8:00 a.m. Eastern Daylight Time (1:00 p.m. British Summer Time) to discuss the positive top-line data from the Phase 2b clinical trial in COPD disclosed in this press release.

Analysts and investors may participate in the conference call by utilizing the conference ID: 13677941 and dialing the following numbers:

  • 1-877-423-9813 or + 1-201-689-8573 for callers in the United States
  • 0 800 756 3429 for callers in the United Kingdom
  • 0 800 182 0040 for callers in Germany

Those interested in listening to the conference call live via the internet may do so by visiting the “Events and Presentations” page on the “Investors” section of Verona Pharma’s website at http://investors.veronapharma.com/events-and-presentations/events and clicking on the webcast link.  Slides highlighting the top-line data will also be posted to the “Events and Presentations” page.

About COPD
Chronic obstructive pulmonary disease (COPD) is a progressive and life-threatening respiratory disease for which there is no cure.1 The condition damages the airways and the lungs, leading to persistent breathlessness, impacting a person’s daily life and their ability to perform simple activities such as walking a short flight of stairs or carrying a suitcase.1 Although COPD is thought to be underdiagnosed, globally, around 384 million people suffer from the disease.2 This number, according to the World Health Organization (WHO), is likely to increase in coming years, with estimates that COPD will become the third leading cause of death worldwide by 2030.1,[3] Current COPD therapies focus on reducing and controlling symptoms. Yet, despite the wide availability of these treatments, many patients continue to suffer acute periods of worsening symptoms known as exacerbations. These exacerbations often lead to emergency department visits or hospital admissions and are also associated with high mortality.4 In the United States alone, the 2010 total annual medical costs related to COPD were estimated to be $32 billion and are projected to rise to $49 billion in 2020.5

About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.

Forward-Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the value of the top-line results from the Phase 2b clinical trial, RPL554 as a new complementary treatment for patients with COPD, projected annual medical costs related to COPD, the results of the Phase 2b trial supporting later stage development of RPL554, the future clinical development and positioning of RPL554, and the treatment potential for RPL554.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of RPL554, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of RPL554, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with RPL554, which could adversely affect our ability to develop or commercialize RPL554; potential delays in enrolling patients, which could adversely affect our research and development efforts; we may not be successful in developing RPL554 for multiple indications; our ability to obtain approval for and commercialize RPL554 in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize RPL554; and lawsuits related to patents covering RPL554 and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on February 27, 2018 relating to our Registration Statement on Form F-1, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. 

For further information, please contact:

  Verona Pharma plc Tel: +44 (0)20 3283 4200
  Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
 Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison
Tel: +44 (0) 20 7710 7600
SNELVeronaPharma@stifel.com
  FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
  Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
  ICR, Inc. (US Media and Investor enquiries)
  James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
  Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com


1
World Health Organization. Chronic Obstructive Pulmonary Disease. http://www.who.int/mediacentre/factsheets/fs315/en/. Accessed September 2017.

2 Adeloye D, Chua S, et al. Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. J Glob Health 2015; 5(2): 020415.

3 World Health Organization. Burden of COPD. http://www.who.int/respiratory/copd/burden/en/. Accessed September 2017.

4 COPD Foundations. Characteristics of COPD Patients Using United States Emergency Care or Hospitalization. https://journal.copdfoundation.org/jcopdf/id/1103/Characteristics-of-COPD-Patients-Using-United-States-Emergency-Care-or-Hospitalization. Accessed September 2017.

5 Center for Disease Control. Increase Expected in Medical Costs for COPD. https://www.cdc.gov/features/ds-copd-costs/. Accessed September 2017.

Monday, March 26th, 2018 Uncategorized Comments Off on $VRNA Positive Top-Line Data Phase 2b Clinical of RPL554 in COPD

$ETST Achieves Record Revenue in February

March 26, 2018

  • ETST revenue increased by 90 percent in the month of February
  • Research demonstrates that ETST’s CBD oil offers top nutritional and supplement value
  • Newly appointed chief sales officer and chief learning officer opening innovative avenues

Earth Science Tech, Inc. (OTC: ETST) announced on March 13, 2018, that February marked the company’s highest-ever sales revenue month. The innovative biotech company focuses on cannabidiol (CBD) nutraceutical and pharmaceutical fields, along with its provision of R&D for certain medical devices. In February, the company achieved a 90 percent revenue increase, from $39,881 to $75,981. The company attributed this increase to its new veteran chief sales officer, supported by a CBD line that has undergone a revamp (http://nnw.fm/Q5tzv).

Earth Science Tech possesses among the highest quality and purity full-spectrum hemp CBD oil on the market. The product is made through critical CO2 extraction processes, making ETST’s CBD oil 100 percent organic and natural. Working alongside DV Biologics and the University of Central Oklahoma, ETST’s research demonstrated that the company is the top nutritional and supplement brand for high-grade hemp CBD oil (http://nnw.fm/AI2dp).

In a news release, Nickolas Tabraue, company president, director and COO, noted February to be a pivotal month, giving praise to newly appointed CSO Jill Buzan while appointing Gabriel Aviles as the company’s chief learning officer. “Jill Buzan has brought so much to our company, and with her experience and knowledge Earth Science Tech, Inc. truly looks to stay innovative and be the trusted CBD brand in the industry,” Tabraue stated, further mentioning that Aviles has begun recording live videos from Monday through Friday on the company’s YouTube channel. Through this endeavor, individuals will have the opportunity to learn more about CBD and will be able to ask questions in real-time, with the videos being shared on social media.

Commenting on the achievement, CSO Jill Buzan stated, “My first month with the company has been an amazing experience with so much potential. I’m excited to see that we were able to achieve the highest revenue month to date, especially due to product delivery delays and slight errors made from the manufacture.”

Tabraue confirmed that the new product revamp has been successful, despite minor errors and manufacturing delays resulting from the increased product demand that was experienced. “We are currently working on our next batch, improving our formula and providing adequate manufacturing time to eliminate any potential errors and to prevent backorders,” Tabraue continued.

Tabraue goes further to say that ETST’s audit continues to move forward and is set to be finalized before the end of March. The audit will be used to submit the company’s planned Tier II Regulation A+ offering, alongside its planned OTCQB up listing. “The team and I greatly appreciate our stakeholders’ loyalty, trust and support while growing with us. We plan on sharing updates as they progress,” reaffirmed Tabraue. With February proving to be a fiscal milestone for Earth Science Tech, Inc., it can be expected that the newly introduced leadership will bring further innovative changes within this fast-growing industry.

For more information, visit the company’s website at www.EarthScienceTech.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Monday, March 26th, 2018 Uncategorized Comments Off on $ETST Achieves Record Revenue in February

$PVOTF Makes Strategic Entry Into California Cannabis Market

VANCOUVER, March 26, 2018 – Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) (“Pivot” or the “Company”), is pleased to announce that the Company has successfully completed the integration of its California subsidiary, ERS Holdings Ltd., under the guidance of Mr. Patrick Rolfes, President of Pivot Pharmaceuticals USA. Mr. Rolfes continues to surround himself with proven, well-respected and experienced leaders in the scientific, legal, financial, and marketing and branding fields. As Pivot prepares for product launch in California in 2018, a consumer-facing brand is being developed for the entire company and will be unveiled in the coming weeks. New websites and marketing materials for our various subsidiaries are also under development. A product list based on our industry-leading and patented bio-cannabis formulation and delivery technologies will be available for consumers and retailers in the coming months.

The Company also wishes to announce that it has secured a listing on the Frankfurt Stock Exchange (“FSE”) and has commenced trading under the symbol “NPAT”.  The FSE is one of the world’s largest trading centres for securities, and the largest of Germany’s seven stock exchanges. The Company believes the listing in Germany will give it greater exposure to a European-based investor audience, fuelling interest and liquidity in Pivot.  The Company’s shares continue to trade on the OTCQB and the Canadian Securities Exchange.

Mr. Rolfes comments that “We are a health and wellness manufacturing company whose branded products incorporate patented scientific processes to bring cannabinoid-based derivatives to the market in discreet and consistent dosages with significant, targeted health benefits and superior bioavailability.”  Mr. Rolfes added that “Pivot’s consumer-facing brands, backed by our patented technologies and formulations, will provide health conscious consumers with natural edible and topical cannabis products delivering exceptional targeted results which will quickly differentiate Pivot in the cannabis space.”

A report from the cannabis industry research firm BDS Analytics estimates sales of cannabis in California to hit USD $3.7 billion by the end of 2018 alone, and predicts that number will increase to USD $5.1 billion in 2019 as more dispensaries come online. For comparison, beer sales in the state hit USD $5 billion in 2017, according to industry research group IBIS World. California, the world’s sixth largest economy with a population of close to 40 million, will form a massive portion of the total market for cannabis in North America.

Dr. Patrick Frankham, Pivot’s CEO, states “As the Company prepares for legalization of cannabis in Canada, we continue to expand our business operations in the US market on a state-by-state basis, where regulations permit. California alone has a population four million people higher than Canada and the potential cannabis market size speaks for itself. During recent strategy sessions with Pivot USA, we finalized plans for Mr. Rolfes and his experienced team to launch Pivot’s consumer-facing brands through Pivot’s wholly-owned California licensed manufacturing facility, coming online later this year. Creating value for shareholders is of the utmost importance and I am confident that their investment will be rewarded in the weeks and months ahead.”

About Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot’s wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. (“PGS” or “Pivot Green Stream”), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. PGS has acquired worldwide rights to “RTIC” Ready-To-Infuse Cannabis powder to oil technology. BiPhasix™ Transdermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral) and Thrudermic Transdermal Nanotechnology (transdermal) for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products.  PGS’ initial product development candidates will include topical treatments for women’s sexual dysfunction (PGS-N005), as well as psoriasis (PGS-N007), and an oral product (PGS-N001) for cancer supportive care. For more information please visit www.PivotPharma.com

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc. or Pivot Green Stream Health Solutions Inc. or Pivot Pharmaceuticals USA Inc., or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Monday, March 26th, 2018 Uncategorized Comments Off on $PVOTF Makes Strategic Entry Into California Cannabis Market

$CIIX to Sponsor at the 2018 National Investment Bankers Association

SAN GABRIEL, California, March 26, 2018 —

ChineseInvestors.com Inc. (OTCQB:CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, announces that it will sponsor at the 2018 National Investment Bankers Association (“NIBA”) meeting taking place on March 27, 2018, in New York City at the Westin Hotel in Times Square.

ChineseInvestors.com, Inc.’s CEO Warren Wang will provide a video interview that will be available for viewing on NIBA’s website highlighting the Company’s business updates including: (1) its newly launched cryptocurrency focused website http://www.newcoins168.com, a Bitcoin and blockchain information and education platform that provides the most up-to-date cryptocurrency news and crypto investment education for the global Chinese community; (2) its recent partnership with Phoenix North America Chinese Channel, one of the most influential and globally renowned Chinese television broadcasters, with plans to broadcast a daily cryptocurrency commentary program, “Bitcoin Big Winner,” and its “Wall Street Daily Program ” with up-to-date roadshow and conference reports; and (3) the Company’s investor relations service plans designed to achieve specific marketing objectives through roadshows, newsletters and TV Broadcasts.

Since 1982, the National Investment Banking Association has been a not-for-profit association comprised of micro-cap and small-cap professionals including Broker Dealers, Investment Bankers, RIA’s, Private Equity Groups, Family Offices, Boutique Corp. Finance, Specialized Investment Brokerages, Venture Capital Groups, Fund Managers, and Capital Market Service Providers, etc. NIBA has hosted 143 investment conferences featuring public and private micro-cap and small-cap companies seeking access to the financial industry. NIBA’s member firms have a 37-year track record of successfully completing thousands of transactions totaling over $15 billion in new capital for emerging growth companies and are responsible for 90% of all IPOs under $20 million.

“CIIX is pleased to sponsor at NIBA’s upcoming New York City meeting and looks forward to the opportunity to network with top micro-cap and small-cap professionals,” says CIIX Founder and CEO Warren Wang. “We look forward to greeting attendees at our booth where they can learn more about CIIX and the incredible opportunities ahead.”

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information, visit ChineseInvestors.com

Visit and register: https://www.newcoins168.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Subscribe and watch our video commentaries: https://www.youtube.com/channel/UCriTFjFHCvDW_LBhiIeuLlQ/featured

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

 

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:

Alan Klitenic
+1-214-636-2548

Corporate Communications:

NetworkNewsWire (NNW)
New York,
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com

Monday, March 26th, 2018 Uncategorized Comments Off on $CIIX to Sponsor at the 2018 National Investment Bankers Association

$STLHF Provides Pilot Plant and Process Testing Update

VANCOUVER, British Columbia, March 26, 2018 — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to provide an update of the extensive process testing work and pilot plant design being performed by the Company’s Scientific Advisory Team.  The Scientific Advisory Team and other technology vendors have been testing raw lithium brines from Standard Lithium’s Projects in California and Arkansas using a new generation of lithium-selective sorbent technologies.  Data gathered from mini-pilot scale testing has demonstrated highly-effective separation of lithium from other cations in the raw brine, in line with previously published and peer-reviewed studies, and has also demonstrated that the solid sorbent materials can be simply made using standard commercial manufacturing processes.  Work has also been completed to test varying physical methods by which raw brine can be mixed with the lithium-selective material to optimise lithium removal.  Testing is ongoing and will be used in the full-scale pilot design (see below).

Standard Lithium is also pleased to announce that they have engaged Zeton Inc. to design and build the full-scale continuous pilot plant for deployment in southern Arkansas.  Zeton Inc. is based in Burlington, Ontario, and is the largest designer and builder of modular pilot/demo scale plants in the world, having completed over 800 projects in over 35 countries.  Design basis engineering has commenced, and it is expected that construction of the various modules will commence in the second half of 2018.

President and Chief Operating Officer, Dr. Andy Robinson, commented, “Standard’s Scientific Advisory Team has been extremely busy over the last six months developing and adapting existing brine processing technologies to integrate modern lithium-selective technologies; both constructing new mini-pilot scale facilities, as well as working with other third-party technology vendors.  We’re now in a position where we have demonstrated proof-of-concept for these technologies and can optimise process flowsheets for the Arkansas and California lithium brines.  We’re also delighted to be working with the team at Zeton Inc. and benefitting from their huge depth of experience when it comes to designing and building continuously operated, fully integrated modular Pilot Plants.  In order to effectively manage the Pilot Plant design and build process, we’ve also added significant senior engineering bench strength to Standard’s team, and we look forward to providing more information on the Pilot Plant progress and flowsheet performance as we move through 2018.

Standard Lithium CEO, Robert Mintak, commented, The agreements and business relationships Standard Lithium has struck over the past year have allowed us to fast-track our development timeline.  Securing projects with existing permitted brine producers has allowed us access to bulk volumes of raw brine from both of our project areas to conduct process work.  Our approach is to intelligently use existing technologies as much as possible and apply project-specific innovations where appropriate; this way, we are not trying to force a technology on the project, but rather to allow the project fundamentals to define the flowsheet.”

Quality Assurance

Dr. Ron Molnar, Professional Metallurgical Engineer (Ontario P.E.# 100111288), is a qualified person as defined by NI 43-101, and has reviewed and approved the scientific and technical information that forms the basis for this news release.  Dr. Molnar is independent of the Company.

About Standard Lithium Ltd.

Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills and modern brine processing technologies.  The Company is currently engaged in the exploration and resource development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities.  The Company is also rapidly conducting resource evaluation on up to 33,000 acres of brine leases located in the Smackover Formation in Southern Arkansas.

Standard Lithium is listed on the TSX Venture under the trading symbol “SLL”; quoted on the OTCQX under the symbol “STLHF”; and on the Frankfurt Stock Exchange under the symbol “S5L”.  Please visit the Company’s website at www.standardlithium.com.

For further information, contact Anthony Alvaro at (604) 240 4793

On behalf of the Board,

Standard Lithium Ltd.

Robert Mintak, CEO & Director

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information.  These forward-looking statements or information may relate to future prices of commodities, accuracy of mineral or resource exploration activity, reserves or resources, regulatory or government requirements or approvals, the reliability of third party information, continued access to mineral properties or infrastructure, fluctuations in the market for lithium and its derivatives, changes in exploration costs and government regulation in Canada and the United States, and other factors or information.  Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties.  Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements.  The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affections such statements and information other than as required by applicable laws, rules and regulations.

Readers are cautioned that a “Qualified Person” (as that term is defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects) has not done sufficient work to specify any mineral resource or reserve on the Properties.

Monday, March 26th, 2018 Uncategorized Comments Off on $STLHF Provides Pilot Plant and Process Testing Update

$NETE Appoints Seasoned Fintech Executive to Board of Directors

MIAMI, FL , March 26, 2018 — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (POS), e-commerce and mobile devices, today announces that Mr. Jonathan Fichman has joined Net Element’s board of directors and will serve as a member of the Company’s Audit, Nominating and Governance, and Compensation committees.

Fichman brings over 20 years of strategic domestic and international finance expertise within Fortune 100 companies, is a Bank of America Merrill Lynch veteran, and a former Wall Street analyst.  His experience includes FinTech, payments, blockchain, wealth management and banking.  Fichman holds a Six Sigma Black Belt accreditation and serves on multiple for profit and nonprofit boards.

Net Element CEO, Oleg Firer, commented, “We are pleased to have Jonathan join our board. He brings extensive, payments, financial, governance and technology experience complementary to our current Board composition and I am confident that he will be a valuable asset to our Company and its shareholders.”

Fichman commented, “Net Element has a great ability to deliver technology-enabled, software-driven solutions that create value beyond just processing payments.  The company’s recently announced plans to create a blockchain payments platform and its recently released next generation cloud-based point of sale payments system will both be impactful innovations for the industry.  I look forward to joining the board of directors and being a key contributor towards the success of Net Element.”

Since 2013, Fichman has served as a managing director of C-Anax Ventures & Advisory, where he assists early-stage companies with corporate strategy, streamlining operations, and financial analysis. Fichman is also an adjunct professor at Florida International University, where he teaches in the Business School with a focus on international management and entrepreneurship.

From 2005 to 2015, Fichman served as a senior vice president of International Business Strategy & Initiatives at Bank of America Merrill Lynch. From 2003 to 2004, he served as a director of Operations, Procurement and Insurance at the Township of Cherry Hill, New Jersey. From 1999 to 2003, Fichman was a vice president of Strategic Initiatives at Actrade Financial Technologies, where he helped create B2B banking products that were at the forefront of commercial payments. Finally, from 1997 to 1999 he was a Senior Wall Street Analyst.  Fichman received his MBA in Finance and Management from the University of Miami School of Business and Bachelor of Arts in Criminal Justice from the George Washington University.

Fichman’s LinkedIn Profile is available at: https://www.linkedin.com/in/jonathanfichman/

The Company’s 8-K filing reflecting the appointment was filed with the Securities and Exchange Commission (SEC) on March 26, 2018 and is available on the SEC’s website.

About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. In the U.S. it aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, our cloud based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500™.  In 2017 we were recognized by South Florida Business Journal’s as one of 2016’s fastest growing technology companies. Further information is available at www.NetElement.com.

Forward-Looking Statements
Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element’s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element’s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element’s ability to successfully expand in existing markets and enter new markets; (iv) Net Element’s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element’s business; (viii) changes in government licensing and regulation that may adversely affect Net Element’s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element’s business; (x) Net Element’s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of further U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Contact: 
Net Element, Inc.
1-786-923-0502
media@netelement.com
Monday, March 26th, 2018 Uncategorized Comments Off on $NETE Appoints Seasoned Fintech Executive to Board of Directors

$DPW Subsidiary Enters Secures 25 Megawatts of Power for Crypto Mining

FREMONT, CA, March 23, 2018 — DPW Holdings, Inc. (NYSE American: DPW) (“DPW” or the “Company“), a diversified holding company, announced that its subsidiary, Super Crypto Mining, Inc. (“SCM”) has entered into an agreement with a U.S. based entity securing the right to 25 megawatts of power in support of SCM’s operations of approximately 20,000 mining rigs at the location.

“We are excited about this new arrangement for many reasons. This not only helps SCM reach our 2018 goals but also provides capacity for future growth. We are proud to be working with a well-respected data facility leveraging efficiencies that result in a symbiotic cost-effective relationship. This is a unique relationship whereby SCM has obtained access to electricity for the miners at costs competitive with global locations, meaning that we can maintain our operations within the U.S. We will have more to share in the coming months specific to the operation as well as “Green Energy” practices that we are employing at the location,” commented Darren Magot, the CEO of SCM.

SCM will be placing at least 2,000 mining rigs at the new location practically immediately. Some of these machines will be supporting our Cloud Mining offering, which we expect will commence on May 1, 2018.

“This is just another example of how Super Crypto Mining is executing on its plans and adding value to the parent company, DPW Holdings,” commented Milton “Todd” Ault III, the Company’s CEO and Chairman. “This new arrangement will allow SCM to build out as it ramps up its operations, dependent on the timing of financing and product availability.”

ABOUT DPW HOLDINGS, INC.
Headquartered in Fremont, CA, DPW Holdings, Inc. is a diversified holding company that, through its wholly owned subsidiary, Coolisys Technologies, Inc., is dedicated to providing world-class technology-based solutions where innovation is the main driver for mission-critical applications and lifesaving services. Coolisys’ growth strategy targets core markets that are characterized by “high barriers to entry” and include specialized products and services not likely to be commoditized. Coolisys through its portfolio companies develops and manufactures cutting-edge resonant switching power topologies, specialized complex high-frequency radio frequency (RF) and microwave detector-log video amplifiers, very high-frequency filters and naval power conversion and distribution equipment. Coolisys services the defense, aerospace, medical and industrial sectors and manages four entities including Digital Power Corporation, www.DigiPwr.com, a leading manufacturer based in Northern California, 1-877-634-0982; Digital Power Limited dba Gresham Power Ltd., www.GreshamPower.com, a manufacturer based in Salisbury, UK.; Microphase Corporation, www.MicroPhase.com with its headquarters in Shelton, CT 1- 203-866-8000; and Power-Plus Technical Distributors, www.Power-Plus.com, a wholesale distributor based in Sonora, CA 1-800-963-0066. Coolisys operates the branded division, Super Crypto Power, www.SuperCryptoPower.com.

Digital Power Lending, LLC, a wholly owned subsidiary of the Company, is based in Fremont, CA, and is a California private lending company dedicated to strategically providing capital to small and middle size businesses for an equity interest in addition to loan fees and interest, www.DigitalPowerLending.com. Excelo, LLC, a wholly-owned subsidiary of the Company, is a national search firm specializing in fulfilling strategic executive, professional and hi-tech placements for businesses delivering world-class services, www.Excelo.com. DPW Holdings, Inc.’s headquarters is located at 48430 Lakeview Blvd., Fremont, California, 94538; 1-877-634-0982; www.DPWHoldings.com. For Investor inquiries: IR@DPWHoldings.com or 1-888-753-2235.

Forward-Looking Statements

The foregoing release contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the acquisition and the ability to consummate the acquisition. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.gov and on the Company’s website at www.DPWHoldings.com.

Friday, March 23rd, 2018 Uncategorized Comments Off on $DPW Subsidiary Enters Secures 25 Megawatts of Power for Crypto Mining